Loading…
One of China's largest retail pharmacy chains, based in Guangdong, selling prescription and OTC medicines.
One of China's largest retail pharmacy chains, based in Guangdong, selling prescription and OTC medicines.
Buys medicines from manufacturers and wholesalers and sells them through its own stores, with prescription drugs paid partly through state medical-insurance accounts and over-the-counter and health products adding higher margins. Growth comes from opening stores and buying regional chains.
In one line: A China-focused CVS/Walgreens.
Moat: narrow (scale, distribution, regulatory licence). Large regional pharmacy network and drug-retail licences create scale advantages over independents.
Headquarters: Guangzhou, Guangdong, China · Employees: 41,141
Size DaShenLin Pharmaceutical (603233.SS) is a China Consumer Staples company (Drugstore Chains) with a market value of $3.80B, the 678th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥21.49 on 6 Nov 2026.
Performance Over six months the shares gained 14.8%, against +6.6% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 11 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +7.0%); the operating margin is 8.1% (peer median 4.8%).
Valuation It trades at 16.6× forward earnings against a peer median of 16.9× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.5 points above its cost of capital (5.4% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥28.7B | CN¥27.5B | CN¥26.5B | CN¥24.5B | CN¥21.2B |
| Revenue growth | — | +4% | +8% | +15% | — |
| Gross profit | CN¥10.9B | CN¥8.92B | CN¥8.55B | CN¥8.34B | CN¥7.60B |
| EBITDA | n/a | CN¥3.82B | CN¥3.42B | CN¥3.47B | CN¥3.11B |
| Net income | CN¥1.43B | CN¥1.24B | CN¥915M | CN¥1.17B | CN¥1.04B |
| Free cash flow | CN¥3.26B | CN¥4.87B | CN¥1.63B | CN¥1.38B | CN¥2.74B |
| Capital expenditure | CN¥584M | CN¥485M | CN¥1.48B | CN¥1.80B | CN¥1.03B |
| Total debt | CN¥12.4B | CN¥12.9B | CN¥13.4B | CN¥10.7B | CN¥9.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| DaShenLin Pharmaceutical 603233.SS | $3.80B | +15% | +7% | 8% | 16.6× | -9.0% |
| Yifeng Pharmacy Chain 603939.SS | $4.91B | +17% | +5% | 10% | 17.2× | -9.2% |
| LBX Pharmacy Chain Joint Stock 603883.SS | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% |
| Yixintang Pharmaceutical 002727.SZ | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% |
| JZJ Chain Drugstore Corporation 605266.SS | $307M | -34% | -5% | 0% | 6.5× | -9.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603233.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.1% | +8.1% | 2nd highest of 11 |
| 6-month return | +14.8% | +6.6% | 4th highest of 11 |
| Distance from 52-week high | -1.3% | -14.3% | highest of 11 |
| Revenue growth (TTM) | +7.1% | +7.0% | 6th highest of 11 |
| Operating margin | 8.1% | 4.8% | 2nd highest of 11 |
| Forward P/E | 16.6× | 16.9× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -9.0% | -8.6% | 6th least demanding of 11 |
| Growth delivered (Del g) | +13.6% | +10.3% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | -22.6 pp | -20.6 pp | 2nd least demanding of 11 |
| ROIC minus cost of capital | +12.5 pp | +7.6 pp | 3rd highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DaShenLin Pharmaceutical 603233.SS | China | $3.80B | +15% | +7% | 8% | 16.6× | -9.0% | +13.6% |
| Sugi 7649.T | Japan | $3.27B | -23% | +9% | 5% | 16.8× | -9.7% | +10.9% |
| Yifeng Pharmacy Chain 603939.SS | China | $4.91B | +17% | +5% | 10% | 17.2× | -9.2% | +13.2% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| TSURUHA 3391.T | Japan | $6.74B | +15% | +114% | 4% | 22.2× | -2.3% | +9.6% |
| MatsukiyoCocokara & 3088.T | Japan | $6.78B | +17% | +5% | 8% | 17.5× | -6.2% | +15.5% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |